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Abstract
Background: Identification of carbapenemase-producing Enterobacteriaceae (CPE) in faecal specimens is challenging.
This fact is particularly critical because low-level carbapenem-resistant organisms such as IMP-producing CPE are most
prevalent in Japan. We developed a modified selective medium more suitable for IMP-type CPE.
Methods: Fifteen reference CPE strains producing different types of β-lactamases were used to evaluate the
commercially available CHROMagar KPC and chromID CARBA as well as the newly prepared MC-ECC medium
(CHROMagar ECC supplemented with meropenem, cloxacillin, and ZnSO4) and M-ECC medium (CHROMagar ECC
supplemented with meropenem and ZnSO4). A total of 1035 clinical samples were then examined to detect CPE using
chromID CARBA and M-ECC medium.
Results: All tested strains producing NDM-, KPC-, and OXA-48-carbapenemases were successfully cultured in the media
employed. Although most of the IMP-positive strains did not grow in CHROMagar KPC, chromID CARBA, or MC-ECC, all
tested strains grew on M-ECC. When faecal samples were applied to the media, M-ECC medium allowed the best
growth of IMP-type CPE with a significantly higher sensitivity (99.3%) than that of chromID CARBA (13.9%).
Conclusions: M-ECC medium was determined as the most favourable selective medium for the detection of IMP-type
CPE as well as other types of CPE.
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Background
Infection with carbapenemase-producing Enterobacte-
riaceae (CPE) has been associated with high rates of
morbidity and mortality [1, 2]. Regular surveillance of
CPE is critically important to prevent the spread of
these pathogens in healthcare settings [3]. The main
reservoir of CPE is the intestinal tract, and faecal
specimens are conventionally used for the screening of
CPE. However, isolation of CPE from faecal specimens is
difficult because CPE usually exists as a small proportion
of the overall bacterial load [4, 5]. Furthermore, among
several types of carbapenemases, enzymes such as
OXA-48 and IMP have low capability of hydrolysing
carbapenems [6]. These data indicate the difficulties in
screening for CPE in stool specimens [3–5, 7].
Several phenotypic methods for CPE screening have
been evaluated, but no standardised method has been
established to date [4, 5]. Even highly carbapenem-
resistant phenotypes such as NDM-type CPE are difficult
to identify if cultured as a small inoculum in selective
medium [8]. A similar phenomenon is observed when
screening for vancomycin-resistant Enterococcus [9]. The
sensitivity of screening largely depends on the minimum
inhibitory concentration (MIC) of the drug for the isolate
and the bacterial load. This phenomenon is especially
important in Japan because the most prevalent CPE in
Japan are IMP-1 and IMP-6- types, which show low-level
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resistance to carbapenems. Furthermore, IMP-6-type
isolates are generally susceptible to imipenem, but re-
sistant to meropenem [10, 11]. Therefore, IMP-type
CPE is occasionally misidentified in laboratory exami-
nations and is referred to as ‘stealth-type CPE’ to draw
attention to this type of CPE [11]. Several reports indi-
cated difficulties in screening for OXA-48-type isolates,
which are widely known to display low-level resistance
[12]. Meanwhile, a reliable phenotypic method for IMP-
type CPE has not been investigated [4]. In this study,
we developed a selective medium for IMP-type CPE.
Methods
Bacterial isolates, clinical specimens, and ethical statements
Four selective culture media (vide infra) were examined
with bacterial isolates as well as clinical faecal speci-
mens. Fifteen CPE isolates of Enterobacteriaceae and
five non-CPE isolates were used (Table 1). The MICs of
meropenem and imipenem for each isolate were deter-
mined using Etest strips (bioMérieux Clinical Diagnostics,
Marcy l’Etoile, France), and the genotypic characteristics
of each isolate with respect to carbapenemase and
extended-spectrum beta-lactamase (ESBL) genes were
determined via PCR as previously described [13].
Faecal samples were collected from 30 hospitals in
northern Osaka in December 2015 through the regional
surveillance project performed by Osaka University, four
regional public health centres, and Osaka Prefectural
Institute of Public Health. Ethical approval was obtained
from the Ethical Review Boards of each institution.
Evaluation of selective agar using bacterial isolates
Bacteria in the stool of colonised patients are typically
present at low abundances [3, 4], although the inoculum
size used to determine CLSI susceptibility breakpoints
and MICs ranged from 104 cells per spot (agar dilution)
to 5 × 105 cells per millilitre (broth microdilution) [14].
Therefore, to simulate experiments using stool samples,
we inoculated each plate with approximately 102 CFU
and compared the CFU counts in selective agar media
as previously described [8]. Overnight cultures of each
isolate in brain-heart infusion broth (BD Diagnostic
Systems, Detroit, MI, USA) were serially diluted and
inoculated in triplicate plates. CFU counts were compared
among Mueller-Hinton agar (MHA) (BD Diagnostic
Systems) as well as two commercial and two in-house
prepared agar media: (1) chromID CARBA (bioMérieux,
Paris, France), (2) CHROMagar KPC (CHROMagar
Microbiology, Paris, France), (3) MC-ECC medium
Table 1 Properties of the bacterial strains used and average recoveries of CFU on each selective agar medium
Strain Species Type of β-lactamase MIC (mg/L) % CFU compared to that of each strain grown in MHA
Carbapenemase ESBL MEPM IPM CHROMagar KPC chromID CARBA MC-ECC M-ECC
1504-16 Escherichia coli IMP-6 CTX-M-15, CTX-M-2 8 0.5 0* 0* 91 97
1502-08 E. coli IMP-6 - 8 0.5 0* 0* 0* 42*
1405-06 E. coli IMP-6 CTX-M-15, CTX-M-2 3 0.38 0* 0* 74 91
1502-25 E. coli IMP-6 CTX-M-2 3 3 44* 112 80 98
1409-10 Klebsiella pneumoniae IMP-6 CTX-M-2 1 0.19 0* 0* 4* 95
1502-02 K. pneumoniae IMP-6 - 4 0.25 0* 0* 3* 123
1409-09 K. pneumoniae IMP-6 CTX-M-2 0.5 0.25 0* 0* 0* 27*
1212-13 K. pneumoniae IMP-6 CTX-M-2 0.5 0.25 0* 0* 8* 66
1412-36 K. pneumoniae IMP-1 CTX-M-2 3 0.5 0* 0* 33* 97
1502-06 K. pneumoniae IMP-1 - 1 1 0* 114 75 74
1011-12 K. pneumoniae KPC-2 - >32 >32 97 93 93 100
BAA-1705 K. pneumoniae KPC-2 - 32 32 109 115 157 155
BAA-2470 K. pneumoniae NDM-1 CTX-M-15 16 32 41 112 119 116
BAA-2471 E. coli NDM-1 CTX-M-15 >32 >32 138 114 170 149
TRKP-54 K. pneumoniae OXA-48 - 16 32 99 89 105 95
1502-04 Enterobacter cloacae - - 2 2 10* 0* 0* 21*
1012-01 Serratia marcescens - - 6 >32 3* 113 127 98
1104-18 E. cloacae - - 0.19 0.5 0* 0* 0* 0*
1004-112 E. coli - CTX-M-2 0.016 0.25 0* 0* 0* 0*
1004-25 K. pneumoniae - CTX-M-2 0.032 0.38 0* 0* 0* 0*
ESBL extended-spectrum β-lactamase, MEPM meropenem, IPM imipenem, MHA Mueller-Hinton agar
*p < 0.01
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(CHROMagar ECC [CHROMagar Microbiology] supple-
mented with 0.25 μg/mL meropenem, 250 μg/mL cloxa-
cillin, and 70 μg/mL ZnSO4), and (4) M-ECC medium
(CHROMagar ECC supplemented with 0.25 μg/mL mero-
penem and 70 μg/mL ZnSO4). Each plate was incubated
at 37 °C for 24 h, and the percent recovery was calculated
as the average colony count of a given isolate divided by
that in MHA. The difference in the CFU count between
MHA and each selective medium was assessed using a
two-tailed Student’s t test with GraphPad Prism software
(GraphPad Software, La Jolla, CA, USA).
Evaluation of selective agar using stool specimens
Clinical faecal specimens from the patients were col-
lected with Seed Swab No. 1 (Eiken Chemical Co., Ltd.,
Tokyo, Japan) and stored at 4 °C until examination. The
samples were inoculated directly from the swab into
chromID CARBA medium and M-ECC medium without
pre-incubation. Positive colonies were selected as de-
fined by the manufacturer’s instructions and examined
for specification of bacterial isolates and antimicrobial
susceptibility using a MicroScan WalkAway Plus system
(Beckman Coulter, Brea, CA, USA). The results were
interpreted according to the 2012 guidelines (M100-S22)
of the Clinical Laboratory Standards Institute (Wayne,
PA, USA). When the isolates showed intermediate or
resistance to meropenem or imipenem, their carbapene-
mase genotypes were analysed by PCR as previously
described [13]. An isolate positive for the blaIMP gene
was further analysed to identify the blaIMP-1 or blaIMP-6
type by sequencing the acquired amplified products using
a primer set targeting blaIMP (IMP-1_469F: TTTATATT
TTTGTTTTGCAGCATTGC; IMP-1_1277R: CGCGTT
GTGGAATACTTTGC). Sensitivity and specificity of
media for blaIMP-type CPE identification were calculated
using GraphPad Prism software.
Results and discussion
We evaluated three major selective media, the chromID
CARBA, CHROMagar KPC, and MC-ECC that was
made in reference to SuperCarba medium [15]. The
NDM-, KPC-, and OXA-48-positive strains were recov-
ered with both chromID CARBA and CHROMagar
KPC, but eight IMP-positive strains were not recovered
in any selective media (Table 1). MC-ECC showed better
recoveries than chromID CARBA and CHROMagar
KPC, although six IMP-positive strains were not recov-
ered. This result is similar to previous reports [7, 16, 17].
IMP-producing CPE was also difficult to detect when a
small number was inoculated.
Several reports indicated that commercially available
SuperCarba, chromID OXA-48, and chromID ESBL are
favourable selective media [2, 12, 15, 18]. Unfortunately,
neither SuperCarba nor chromID OXA-48 was available
in Japan at the time of our research, and chromID ESBL is
not appropriate for CPE detection due to the high preva-
lence of ESBL in Japan [19]. Therefore, we developed MC-
ECC medium as an in-house SuperCarba. Surprisingly,
however, a significant reduction in the apparent CFU was
observed in six out of the 10 IMP-positive isolates plated
on MC-ECC medium. This result could be explained by
our supplementary experiment indicating that the MIC of
meropenem for IMP-type strains decreases when cloxacil-
lin is added (Additional file 1: Table S1). Therefore, we
removed cloxacillin from the MC-ECC medium to in-
crease the sensitivity and referred to the resulting medium
as M-ECC. As a result, all CPE strains could be detected
in M-ECC medium (Table 1).
In the next series of experiments, a total of 1024 stool
samples and 11 rectal swabs were examined to compare
the capability of M-ECC and chromID CARBA to detect
CPE in stool samples. The average time interval from
sample acquisition to examination was 4.66 ± 2.66 days.
Positive colonies were obtained in 149 specimens using
M-ECC, though six of them did not contain CPE follow-
ing further examination (Additional file 2: Table S2). Five
of the six false-positive samples whose MIC against mero-
penem was more than 0.25 μg/mL could be grown in M-
ECC medium. One sample contained susceptible Entero-
bacteriaceae alone, which might be grown together with
carbapenem resistant non-fermenting gram-negative rods
such as Pseudomonas aeruginosa. In contrast, only 20
specimens gave positive colonies when chromID CARBA
was used; all contained CPE. M-ECC medium provided
significantly higher sensitivity (99.3%) than chromID
CARBA (13.9%) (Table 2).
Table 2 Sensitivity and specificity of M-ECC and chromID CARBA to detect blaIMP-positive CPE in stool specimens

















Positive 20 0 13.9 (8.7–20.6) 100.0 (99.6–100.0) 100.0 (83.2–100.0) 87.8 (85.6–89.7) NA
Negative 124 891
CI confidential interval, PPV positive predictive value, NPV negative predictive value, PLR positive likelihood ratio, NA not applicable
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Removing cloxacillin may contribute to high sensitivity
of M-ECC medium. Meanwhile, it did not contain inhib-
itors preventing the overexpression of AmpC and efflux
pumps expressed by bacteria and non-carbapenemase
producing CRE can grow in M-ECC medium [20, 21].
Therefore, further identification such as PCR was necessary
to confirm isolates as CPE.
This study contains several limitations. First, we
examined M-ECC medium with stool specimens con-
taining IMP-positive CPE alone because other types
are rarely found in Japan. Secondly, the amount of
clinical specimens directly applied in each assay was
not perfectly identical because the stool specimens
were not homogeneous, and the inoculated speci-
mens were not similar even though we used the
same swab. Finally, we did not sufficiently evaluate
M-ECC medium with non-CPEs and it may show
lower specificity. However, in order to obtain accur-
ate epidemiology, sensitivity is more important, and
M-ECC medium should be the most suitable for CPE
screening in this study.
Conclusions
Our results indicated the difficulty in detecting IMP-
type CPE with available selective media. However, we
successfully developed a more selective medium, M-ECC
medium, for IMP-type CPE, which would be useful in
IMP-type CPE prevalent regions like Japan.
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